Skip to the page

Data / Drug companies / Ingenus Pharmaceuticals, LLC

Ingenus Pharmaceuticals, LLC: 141 products in the FDA NDC directory, labeler code 50742

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Ingenus Pharmaceuticals, LLC (labeler code 50742) lists 141 products in the FDA National Drug Code Directory, covering 58 finished drugs by generic name. By type: 137 prescription drugs, 4 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 16, 2026.

The request: Watch Ingenus Pharmaceuticals, LLC (FDA labeler code 50742): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
50742
Products in commercial distribution
141
Packages
234
Finished drugs by generic name
58
Prescription products
137
Over the counter products
4
Controlled substance products
Schedule II 8, Schedule III 9, Schedule IV 6
Flagged as original packager
139 of 139 products that carry the flag
Started marketing in the last 12 months
4
Products with a marketing end date set
1
Earliest marketing start
September 23, 2015
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)12890.8%
New drug applications (NDA)75%
Authorized generics (NDA)32.1%
Other unapproved drugs32.1%

Products by type

TypeProductsShare
Prescription drugs13797.2%
Over the counter drugs42.8%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet3122%
Tablet, extended release3122%
Patch, extended release149.9%
Tablet, film coated139.2%
Capsule, extended release107.1%
Patch96.4%
Capsule85.7%
Solution53.5%
Film42.8%
Solution/ drops42.8%
Tablet, orally disintegrating32.1%
Tablet, film coated, extended release32.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Progesterone50742-359InsertGeneric drugs (ANDA)October 16, 2026
Nicotine Transdermal System50742-670PatchGeneric drugs (ANDA)May 19, 2026
Nicotine Transdermal System50742-669PatchGeneric drugs (ANDA)May 19, 2026
Nicotine Transdermal System50742-668PatchGeneric drugs (ANDA)May 19, 2026
Estrogens, conjugated50742-391Tablet, film coatedGeneric drugs (ANDA)October 16, 2025
Estrogens, conjugated50742-390Tablet, film coatedGeneric drugs (ANDA)October 16, 2025
Estrogens, conjugated50742-389Tablet, film coatedGeneric drugs (ANDA)October 16, 2025
Estrogens, conjugated50742-388Tablet, film coatedGeneric drugs (ANDA)October 16, 2025
Estrogens, conjugated50742-387Tablet, film coatedGeneric drugs (ANDA)October 16, 2025
Prednisolone sodium phosphate ODT50742-385Tablet, orally disintegratingAuthorized generics (NDA)September 15, 2025
Prednisolone sodium phosphate ODT50742-384Tablet, orally disintegratingAuthorized generics (NDA)September 15, 2025
Prednisolone sodium phosphate ODT50742-383Tablet, orally disintegratingAuthorized generics (NDA)September 15, 2025
Dehydrated Alcohol50742-539Injection, solutionGeneric drugs (ANDA)July 9, 2025
Diltiazem Hydrochloride50742-566Capsule, extended releaseGeneric drugs (ANDA)July 3, 2025
Diltiazem Hydrochloride50742-565Capsule, extended releaseGeneric drugs (ANDA)July 3, 2025
Diltiazem Hydrochloride50742-564Capsule, extended releaseGeneric drugs (ANDA)July 3, 2025
Formoterol Fumarate50742-394SolutionGeneric drugs (ANDA)June 5, 2025
Oxcarbazepine50742-613Tablet, extended releaseGeneric drugs (ANDA)June 1, 2025
Oxcarbazepine50742-612Tablet, extended releaseGeneric drugs (ANDA)June 1, 2025
Oxcarbazepine50742-611Tablet, extended releaseGeneric drugs (ANDA)June 1, 2025
Hemiclor50742-285TabletNew drug applications (NDA)March 17, 2025
Arformoterol Tartrate50742-395SolutionGeneric drugs (ANDA)March 1, 2025
Fentanyl50742-555Patch, extended releaseGeneric drugs (ANDA)February 11, 2025
Fentanyl50742-553Patch, extended releaseGeneric drugs (ANDA)February 10, 2025
Fentanyl50742-551Patch, extended releaseGeneric drugs (ANDA)February 5, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.